pVir and Bloody Diarrhea in Campylobacter jejuni
Enteritis by Tracz, Dobryan M. et al.
The plasmid pVir may play a role in the virulence of
Campylobacter jejuni, a leading cause of bacterial gas-
troenteritis. The pVir plasmid was identified in 17% of 104
C. jejuni clinical isolates studied and was significantly asso-
ciated with the occurrence of blood in patient stool, a mark-
er of invasive infection. The pVir plasmid was not
associated with greater occurrence of diarrhea, fever, pain,
vomiting, or need for patient hospitalization. Isolates con-
taining pVir were also associated with the presence of a
tetracycline-resistance plasmid, but pVir did not transfer
with tetracycline-resistance plasmids to recipient strains of
C. jejuni. The association of pVir and bloody stool suggests
that pVir may be clinically relevant in C. jejuni infections. 
C
ampylobacter jejuni is a major foodborne pathogen
and a leading cause of bacterial gastroenteritis (1,2).
Infection with C. jejuni can result in a wide array of clini-
cal symptoms, including diarrhea, fever, abdominal pain,
and vomiting, as well as bloody stool with severe invasive
infection (3). Various virulence factors, which allow for
adherence, colonization, and invasion of the intestinal
epithelium, have been proposed to contribute to the patho-
genesis of C. jejuni (4). Potential virulence components
include flagella (5,6), invasion proteins (7), and toxins
(8,9). Although the genome of C. jejuni has been
sequenced (10), its mechanisms of pathogenicity remain
poorly understood (11).
A number of bacterial enteric pathogens contain plas-
mids that contribute to pathogenesis, including Shigella sp.
(12), Salmonella sp. (13), and enteropathogenic
Escherichia coli (14). No evidence was seen for the
involvement of plasmids in the virulence of C. jejuni until
Bacon et al. (15) identified plasmid pVir in strain 81-176.
pVir is an ≈37.5-kb plasmid that contains components of a
type IV secretion system (T4SS) (15,16) known to be
important for the virulence of a number of major bacterial
pathogens (17). Bacon et al. (15) suggested that the pVir
plasmid is important in vitro for both adherence and inva-
sion of intestinal epithelial cells in culture. In a survey of
fresh clinical isolates of C. jejuni from Thailand, 10% (n =
58) contained pVir (15). 
C. jejuni gastroenteritis is primarily self-limiting and is
usually treated by supportive therapy (fluid and electrolyte
replacement) (3). Erythromycin is the drug of choice for
treating severe clinical infections with C. jejuni (18), and
fortunately the prevalence of erythromycin resistance has
remained low (19). Worldwide, tetracycline resistance in
C. jejuni is high: 56% in Canada (20) and up to 95% in
Thailand (21). In Alberta, Canada, only 8.6% of human
clinical isolates were tetracycline-resistant in 1981 (22). In
C. jejuni, tetracycline resistance is primarily mediated by
plasmids that carry the tet(O) gene (23,24). The Tet(O)
protein binds to the bacterial ribosome and displaces tetra-
cycline (25,26). The aim of this study was to investigate
the prevalence of the pVir plasmid in C. jejuni isolated
from clinical specimens in Alberta and the relationship of
pVir to the clinical expression of the disease in gastroen-
teritis. 
Materials and Methods
Source of C. jejuni Isolates
We obtained a random sample of 104 human isolates of
C. jejuni (fresh and frozen at –70°C in double-strength
skim milk) cultured from stool samples from 1999 to 2002
at the University of Alberta Hospital and Provincial
Laboratory for Public Health (Microbiology) in
Edmonton, Alberta, Canada, for this study. All stool spec-
imens were routinely cultured for enteric pathogens tested
according to standard laboratory protocols. Most C. jejuni
isolates were from northern Alberta and represented ≈10%
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Canadaof  C. jejuni infections in Alberta reported annually to
Health Canada. The Health Research Ethics Board
(Biomedical Panel) of the University of Alberta approved
the protocol for access to human isolates and collection of
patient information for this study.
Collection of Clinical Data
Clinical data were collected by letter or phone from
family physicians’ offices and emergency medical records
and included information on age, sex, place of residence,
travel within the last month, coexisting conditions, symp-
toms (diarrhea, bloody diarrhea, pain, fever, vomiting) and
their duration (interval from symptom onset to initial eval-
uation), hospitalization (if needed), antimicrobial therapy,
and complications. Fever was defined as a complaint of
fever stated by the patient or a documented temperature of
>38°C. Blood in the stool was observed by the patient and
reported to the attending physician. The investigators con-
ducting the chart review and laboratory analyses (pVir
screening, antimicrobial susceptibility testing) were blind-
ed to each other’s data. 
Culture of C. jejuni Isolates
Isolates of C. jejuni were spread on brain heart infusion
agar (Difco-Becton-Dickinson, Sparks, MD, USA), sup-
plemented with 0.4% yeast extract (Difco), and incubated
at 37°C in microaerobic conditions (5% CO2, 10% H2,
85% N2) for 48 h. Isolates were not passaged more than
once. All isolates were stored frozen in brain heart infusion
broth (Difco) with 20% glycerol at –80°C.
Antimicrobial Susceptibility and Plasmid Isolation
C. jejuni susceptibility was tested by using the disk dif-
fusion method; the following antimicrobial disks (Oxoid,
Nepean, Ontario, Canada) were included: tetracycline (30
µg), kanamycin (30 µg), erythromycin (15 µg), chloram-
phenicol (30 µg), and nalidixic acid (30 µg). All nalidixic
acid-resistant isolates were further tested for resistance to
ciprofloxacin (1 µg). Susceptibility testing to all antimicro-
bial agents was carried out on Mueller-Hinton agar plates
that were spread with a 0.5 McFarland standard suspension
of C. jejuni in phosphate-buffered saline (Sigma, St. Louis,
MO, USA) and incubated for 48 h at 37°C under microaer-
obic conditions. Zones of inhibition were measured as
described by Gaudreau and Gilbert (27). Plasmid isola-
tions were performed by using a Qiagen Midi or Mini
Plasmid Kit (Qiagen, Mississauga, Ontario, Canada), by
alkaline lysis (28) or by a method used for Helicobacter
pylori (29). Tetracycline resistance detected by disk diffu-
sion was confirmed by Etest (Oxoid) and conventional
agar dilution.
DNA-DNA Hybridizations for pVir
Purified plasmid DNA from C. jejuni clinical isolates
was applied to nitrocellulose paper (Osmonics,
Westborough, MA, USA) and air dried. Plasmid
pMS11EH was used as a negative control, and plasmid
DNAisolated from C. jejuni 81-176 was used as a positive
control. Plasmid DNA was denatured in 0.5 mol/L NaOH,
0.15 mol/L NaCl for 5 min, neutralized twice in 10
mmol/LTris-HCl, 0.15 mol/L NaCl, pH 7.5 for 5 min each
time, soaked in 2× SSPE solution (20× SSPE consists of
3.0 mol/L NaCl, 0.2 mol/L NaH2PO4, and 0.02 mol/L
EDTA) for 5 min, air dried, and baked overnight at 65°C.
The  cjp5 (virB11) DNA probe was prepared with
primers virB11 Fwd (5′ GAACAGGAAGTGGAAAAAC-
TAGC 3′) and virB11  Rev (5′ TTCCGCATTGGGC-
TATATG 3′) (15) that were used to amplify by polymerase
chain reaction (PCR) a 708-bp product from within the
cjp5 gene on pVir. Conditions for the PCR were as fol-
lows: initial denaturation at 95°C for 1 min, followed by
30 cycles of denaturation (1 min, 95°C), annealing of
primers (1 min, 50°C) and primer extension (1 min, 72°C).
PCR was performed in a BioRad Gene Cycler (BioRad,
Mississauga, Ontario, Canada). The cjp5 PCR product was
purified with a PCR purification kit (Qiagen) and eluted
with TE (Tris-EDTA) buffer. DNA was denatured after
boiling for 5 min, and the tube was then placed directly on
ice. A random primers DNA labeling system (Gibco,
Burlington, ON) was used to prepare the 32P-labeled cjp5
DNA probe. The 32P-labeled cjp5 DNA probe was used
immediately in DNA-DNAhybridizations to screen isolat-
ed C. jejuni plasmids for the presence of pVir, under the
same stringency conditions defined by Bacon and cowork-
ers (15). Hybridizations were performed in a solution con-
sisting of 6× SSC (20× consists of 3.0 mol/L NaCl and 0.3
mol/Lsodium acetate), 5× Denhart solution (50× Denhardt
solution consists of 1% wt/vol Ficoll 400 (Sigma),
1% wt/vol polyvinylpyrrolidone (Sigma), and 1% wt/vol
bovine serum albumin (Sigma, Fraction V), 0.1% sodium
dodecyl sulfate (SDS, BioRad) and 100 µg/mL herring
sperm DNA (Invitrogen, Burlington, Ontario, Canada).
The 32P-labeled cjp5 DNA probe was added directly to the
hybridization solution in the tube, mixed, and incubated
overnight (18 h) at 50°C. The probed nitrocellulose paper
was washed in 0.5× SSC 4 times, dried, and then exposed
to BioMax MS Film (Eastman Kodak Company,
Rochester, NY, USA) overnight at –70°C.
Identifying Tetracycline-Resistance Plasmids
Tetracycline-resistance plasmids were identified by a
PCR screen for the tet(O) gene on purified plasmid prepa-
rations. Primers tet(O) Fwd (5′ GGCGTTTTGTTTATGT-
GCG 3′) and tet(O) Rev (5′ ATGGACAACCCGACAGA
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tet(O) gene from isolated C. jejuni plasmid DNA (15,30).
PCR conditions were the same as for the cjp5 PCR
described above. Gel electrophoresis was used to confirm
the presence of an ≈40-kb plasmid.
Transfer of Plasmids between C. jejuni Strains
The transfer of plasmids from C. jejuni clinical isolate
23-51 (containing both a tetracycline-resistance plasmid
and pVir) to C. jejuni UA 543 (a nalidixic acid–resistant,
tetracycline-susceptible recipient strain with no plasmids)
was carried out (23). Suspensions of donor strain 23-51
and UA 543 recipient strains were mixed in ratios of 1:4
and 1:6, centrifuged, and resuspended in 100 µLof Lennox
broth (Difco). Mating suspensions were inoculated onto a
0.22-µm Millipore filter (Millipore Corporation, Nepean,
Ontario, Canada), placed on brain heart infusion agar, and
incubated for 24 h. Cultures were resuspended in 1 mL of
phosphate-buffered saline, diluted, and plated onto
Mueller-Hinton agar containing 25 µg/mLtetracycline and
50 µg/mL of nalidixic acid. Plasmids were isolated from
the transconjugants by a Qiagen Mini Kit. The cjp5 DNA
probe was used to screen for pVir as described above. 
Statistical Analysis
The Fisher exact test was used to test the significance
(p<0.05) of the association between pVir and clinical
symptoms, association of pVir and tetracycline-resistance
plasmids, and the frequency of tetracycline resistance from
this study and a previous study (22). 
Results
Clinical Data
The patients were 7 months to 87 years of age (average
35 years); 47% were female. Ninety-five percent of the
patients resided in Alberta, and the remaining 5% were
from other Canadian provinces. Only 10 patients reported
a history of travel outside Canada before becoming ill,
namely to Mexico (3 patients), Alaska, Nicaragua,
Ecuador, England, India, Lebanon, and Africa (1 patient
each). The most commonly reported clinical symptom was
diarrhea (99%); the exception was in an 86-year-old
woman, who had an ileus. Other commonly reported
symptoms were abdominal pain (83%) and fever (77%).
Bloody stool was reported in 27% of patients and vomiting
in 30% of patients; 18% of patients were hospitalized for
treatment of severe dehydration. Fifty-eight patients
received antimicrobial therapy: 34 ciprofloxacin (1 was
switched to erythromycin after culture results, 2 received
ciprofloxacin in combination with metronidazole), 20
macrolides (13 erythromycin, 5 clarithromycin, 3
azithromycin), 2 metronidazole (1 in combination with
cephalexin), 1 amoxicillin, and 1 cotrimoxazole. Sixteen
patients had other associated conditions: 4 cardiac disor-
ders (2 arrhythmias, 2 ischemic heart disease), 3 hyperten-
sion (1 also had chronic obstructive pulmonary disease), 3
diabetes, 2 neoplasms (1 leukemia, 1 Wilm tumor), 2 gas-
trointestinal disorders (1 ulcerative colitis, 1 irritable
bowel), 1 hepatitis C, and 1 seizure. Campylobacteremia
with febrile seizures developed in a previously healthy
patient.
Antimicrobial Susceptibility 
The antimicrobial susceptibility of 104 human isolates
of C. jejuni is shown in Table 1. Tetracycline resistance
was identified in 63 isolates (60%); of these, 4 isolates
were also resistant to nalidixic acid, 2 isolates were also
resistant to kanamycin, and 1 isolate was also resistant to
both nalidixic acid and kanamycin. Three of the 4 nalidix-
ic acid–resistant isolates were also resistant to
ciprofloxacin. In the tetracycline-sensitive isolates, no
resistance to other antimicrobial agents was detected.
Plasmid Content 
Tetracycline-resistance plasmids were found in 50
(79%) of 63 tetracycline-resistant isolates. DNA-DNA
hybridizations for the cjp5 gene on pVir determined that 18
(17%) of 104 C. jejuni isolates contained the pVir plasmid.
Stocked frozen clinical isolates had a slightly higher fre-
quency of pVir than fresh clinical isolates (18% vs. 13%,
respectively), most likely because of sampling error.
Tetracycline-resistance plasmids were found in 17 (94%)
of 18 pVir-positive C. jejuni isolates compared with 33
(38%) of 86 pVir-negative isolates. The presence of pVir
plasmids was associated with the presence of tetracycline-
resistance plasmids (p<0.00001). Alternatively, 33 (66%)
of the 50 isolates that contained tetracycline-resistance
plasmids did not contain pVir, demonstrating that plasmid-
mediated tetracycline resistance does not occur exclusive-
ly with pVir.
Relationship of Signs and Symptoms
to Plasmid Content 
Pain, diarrhea, vomiting, and fever were equally likely
to occur in all C. jejuni infections, regardless of the pres-
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with pVir-positive C. jejuni strains had bloody stool, as
opposed to 21% of patients infected with pVir-negative
C. jejuni strains (p = 0.011). pVir was not associated with
age, sex, antimicrobial therapy, coexisting conditions, or
travel. The patient with campylobacteremia and febrile
seizures was infected with a pVir-negative C. jejuni. None
of the patients infected with pVir-positive C. jejuni strains
had a history of travel outside of Alberta in the week pre-
ceding the illness, and all of the patients who traveled out-
side of Alberta were infected with pVir-negative C. jejuni
strains.
Transfer of Plasmids between C. jejuni Strains
Tetracycline-resistant transconjugants contained ≈40-
kb plasmids that carried tet(O) but were negative for pVir
in DNA-DNAhybridizations with the cjp5 probe (data not
shown). This finding confirmed the finding of Bacon et al.
(15) that pVir could not be transferred with tetracycline-
resistance plasmids in conjugal mating between C. jejuni
strains.
Discussion
The role of pVir in human C. jejuni infections has not
been investigated previously. Bacon et al. (15,16) present-
ed evidence for the role of pVir in the virulence of C. jeju-
ni based on in vitro cell-culture experiments and limited
animal data with the ferret model (15). In our study, symp-
toms associated with C. jejuni infection were correlated
with the presence or absence of pVir plasmids. Symptoms
varied from mild discomfort to severe cases with bloody
diarrhea. Travel and coexisting medical conditions were
not predictors of severity of C. jejuni infections and were
not associated with a higher frequency of blood in the stool
or pVir-positive C. jejuni infections. Although the pVir vir-
ulence plasmid did not correlate with most clinical symp-
toms, patients infected with a pVir-positive C. jejuni strain
were more likely to produce bloody stool than those infect-
ed with a pVir-negative strain. The time course of the dis-
ease may have affected whether or not blood was observed
in the stool sample. The clinical data collected reflect both
the observations of the patient as reported to the physician
and the physician’s records. Accordingly, these conclu-
sions are based upon the necessary limitations of this ret-
rospective study of patients from different unconnected
study sites within a region, with perhaps some differences
in diagnostic definitions.
Bloody stool in C. jejuni gastroenteritis indicates the
progression of the infection into the tissues of the colon
and rectum (3). This invasion of the intestinal epithelium
is responsible for the mucosal damage and inflammatory
lesions seen in C. jejuni infections and is a major compo-
nent of pathogenesis, although the mechanism is currently
unknown (11). pVir was previously found to be important
for the in vitro invasion of intestinal epithelial cell lines
(15,16). The association of pVir in C. jejuni with bloody
diarrhea in a clinical setting supports the role of pVir for in
vivo epithelial cell invasion and stresses its potential as a
marker for the risk of developing a more severe clinical
infection.
The lack of association of pVir with bloody stool in a
small proportion of patients suggests that other virulence
determinants are likely to be involved in severe C. jejuni
infections, as are several other host factors that determine
the clinical expression of the disease (3). Further studies
are necessary to clarify these aspects of clinical C. jejuni
infection.
Large variations in invasion frequency have been
observed among strains of C. jejuni (4). Fearnely et al. (31)
found that C. jejuni strains can either invade cell cultures
at high frequencies (hyperinvasive) or have low invasive
potential. Subsets of the C. jejuni strains may exist that use
different mechanisms to produce disease (15,32). Whether
or not the pVir virulence plasmid is the defining feature of
a hyperinvasive subset of C. jejuni strains remains to be
determined.  
The finding that the pVir virulence plasmid is present in
C. jejuni isolates containing a tetracycline-resistance plas-
mid is of considerable interest. One potential explanation
for this association is the impact on the invasive ability of
the strain. Variation in the invasion frequencies of C. jeju-
ni 81-176 pVir gene mutants has been observed (33) and
may be due to the functional redundancy of T4SS genes
found on pVir and a tetracycline-resistance plasmid (16).
This finding may, in part, explain the dependence of pVir
on the tetracycline-resistance plasmid observed in this
study. 
The prevalence of tetracycline resistance in C. jejuni in
our study (60%) represents a significant increase from
8.6% in 1981 (p<0.0001) (22), but the frequency of resist-
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These results confirm those of other Canadian studies that
have identified increasing levels of tetracycline resistance
and low levels of erythromycin resistance (20,34,35).
Considering that erythromycin is the drug of choice for
treating C. jejuni gastroenteritis, that its efficacy has not
been compromised by the emergence of resistance is sur-
prising. In our study, a low level of resistance to
ciprofloxacin, commonly prescribed to prevent travelers’
diarrhea, is also a surprising finding. A temporal link
between veterinary use of fluoroquinolones and the emer-
gence of fluoroquinolone resistance in human isolates of
C. jejuni coincided with the licensing of fluoroquinolones,
such as enrofloxacin, in the late 1980s and early 1990s in
the Netherlands, Spain, United Kingdom, the United
States, and Canada (36). In the eastern Canadian province
of Quebec, resistance to ciprofloxacin increased from 13%
in 1995 to 47% in 2001 (20,37). Approval for fluoro-
quinolone as a therapeutic agent for use in agriculture in
Canada was withdrawn in 1997 (38) and may explain the
low prevalence of ciprofloxacin-resistant C. jejuni isolated
from human specimens in the western Canadian province
of Alberta. 
Serotyping was not conducted in our study since on its
own it is not a useful discriminating marker for the ability
of  C. jejuni isolates to cause severe gastroenteritis.
Molecular subtyping studies in the United States reported
virtually identical isolates of C. jejuni in locally purchased
retail poultry products and human infections (39). Future
studies will continue to investigate the association of pVir-
positive C. jejuni infections with the presence of blood in
stool and employ a variety of genotypic tools (molecular
typing, DNA microarrays) and phenotypic assays (i.e.,
invasion) to identify the characteristics of C. jejuni isolates
from animal and human sources that allow them to be
effective pathogens in humans. 
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